REMINDER: Our user survey closes on Friday, please submit your responses here.
Thought I would pop in... surprised there hasn't been any RNS update on plans for trials but we will see. I'm in the no news is good news camp but wallowing down at 20m market cap with FDA trial approved CAR-T and other progressing treatments such as CBR really is too low. I'm not at a JHFH £1.80 level but would have thought we we would have been high single digits by now.
Https://www.londonstockexchange.com/news-article/HEMO/placing-to-raise-us-4-2-million/16354098
...is in a holding pattern. Wedged into seats 3P.
Definition: Holding patterns are flown as a delaying tactic, be it for ATC requirements such as airspace saturation or approach delays, as the published termination of a missed approach procedure to be flown whilst coordinating further clearance, at pilot request to allow time for completion of abnormal procedures or at any other time that a delay in flight progress is required.
This is Flight H3MO and we are awaiting our landing slot. Hopefully Air Traffic Control will update us next week. Have a good weekend all.
Don't engage JHFH. I know you have always been passionate about HEMO, and probably a little too half glass full most of the time, but HEMO is CLINICAL, it will go into trials, it will get Prevail funding and above 3p. Don't waste your time arguing the toss with them.
It's fair game, its a share. Anyone can short if they want to... the key is to watch them burn when the SP does improve. Assuming CAR-T works... which it has been proven to do so in lab/mice, then it will be an upward SP. I'm a big supporter of the company with 100k of value tied up (not the levels of Dhub, you, India etc but meaningful for me). I dont trade, havent sold... and believe that we will be 5x this price. The question is when. Could be short-term but more likely another 12m +. It will come. The critical piece will be funding... I believe it will be at a premium to today's price and whilst dilutive, will provide funds to deliver.
The irony is I dont really care about CAR-T. Nice to have... CBR is where the value will be. If CBR works. £1 party that is often quoted, even with dilution would be a possibility. Many steps and years to get there but wow... the promise is incredible.
We will see. Back your winners, ditch the losers. I'm off to Cheltenham soon... HEMO is a gold cup winner, not this year but in the future :-)
Https://www.londonstockexchange.com/news-article/HEMO/cbr-brain-delivery/16335503
I can answer that one Hulver. An individual that goes through 3% with any purchase that takes the shareholder through the threshold (even if 1 single share that triggers it) is mandated to disclose their shareholding . They then have to announce eevry time their share purchase goes through another 1% e.g. 4%, 5% or down if through a 1% threshold too.
Its different for professional investment houses. 5% is the threshold and then only if they go through 10%.
The 3%/5% threshold can also be triggered if a concert party holds these e.g. husband and wife have 1.5% each or two companies with common shareholders have 1.5% each. i.e. individuals working in concert (together) to build a stake in a listed company.
"Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group, announces that it has demonstrated in vivo that its proprietary Chimeric Bait Receptor ("CBR") can be delivered intranasally in the form of messenger RNA ("mRNA") for the potential treatment of airborne viral infections."
The CLINICAL stage biopharma...
Plenty of coverage in the usual penny shares magazines e.g. below. Have emailed a few contacts at the Times, Guardian, FT to see if we can get in one of the broad sheets. It is good news for a UK listed pharma company after all and surely worth a column inch in the financial section.
https://www.proactiveinvestors.co.uk/companies/news/1040611/hemogenyx-pharma-soars-on-fda-trial-consent-1040611.html
Personally, I would do a share consol on the next round of funding. 5:1 or 7:1. Reduce the number of shares in circulation, increase the SP and move HEMO out of the penny share space. Optically looks better if the SP was 20/30p rather than 4p.
130m shares traded yesterday from 1.18bn in circulation, so 11% traded yesterday. Highest volume in a year.
191m shares are not in public hands ie management, which increases the % to 13% swapping 1,2,3p to 4p+ average SP. If you wrap in the bigger shareholders on here who have about 100M between them then that’s nearer 15% of free float in a day.
Expect an update M/T from management on next steps. Patient recruitment, funding option, timeline, nature of trials.
Obviously a lot selling on news yesterday which personally I found disappointing especially with SP performance but a stronger base for growth.
Onwards and upwards is the plan. Funding is critical and the pricing of funding will be the interesting bit. At what price. A placing discount or Prevail premium.
Wow... that is is very unusual. Just tried the same with HL and they will take all my 3.3M at 3.85. NEVER has that been an option. NEVER. I think that tells you something!
Obviously don't have as deep pockets as you Dhub :-)
That's the point Moors. Recycling out the cheaper shares being held, increasing the base hold level SP. Next RNS will be how the trials will be funded and Prevail as a partner. Up we go. Imagine funding will be at 6p given their first tranche. A waiting game... Phase I trials successful = ROCKET.
CBR update along the way.
CAR-T is just the beginning. I'm not cashing out until CBR gets there... 'Microsoft of Pharma' as JHFH puts it. Effectively a panacea to viruses that also works on cancer. You genuinely can't put a price on that. Appreciate that's another 3-5 years but DVS would be right in 'valuing at Billions, not Millions' at that point.